Proteomic Study Published in Nature Paves the Way for New Treatment for Incurable Leukaemia Using an Epigenetic Inhibitor
A study published in Nature by Cellzome and others has identified that a small molecule inhibitor of BET proteins could potentially be used to treat the aggressive and often incurable mixed lineage (MLL-fusion) leukaemia.
The molecular association between BET proteins and factors involved in MLL-fusion leukaemia, which led to the discovery, was unravelled in a collaboration with GSK, the Gurdon Institute of the University of Cambridge, as well as the Departments of Haematology of the Addenbrookes Hospital, the University Hospital Ulm, the Erasmus University Medical Center and the Cardiff University School of Medicine.
Commenting on the results, Dr. David Simmons, CSO of Cellzome said: “This publication shows how our chemoproteomic technology can guide epigenetic drug discovery. This new and exciting field of biology offers great potential for developing novel therapeutic interventions as ‘personalised epigenetic medicines’, and I am pleased that the expertise we have built at Cellzome is making a significant contribution at the forefront of this field.”
Most read news
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Properties of unusual virus revealed in research
CryoLife Enhances Management Team with Promotions - New Vice Presidents Provide Added Focus to Key Growth Drivers
Wolfgang Wienand appointed head of Siegfried research and development

Viruses Are the Better Antibiotic - Development of Novel Therapeutics Boosted With Millions of Euros
